Variant-guided antisense oligonucleotides selectively lower mutant ATXN3 in patient-derived neurons for spinocerebellar ataxia type 3
- Long-read nanopore sequencing of SCA3 patients from three European countries mapped many ATXN3-linked SNPs into three haplotype blocks tied to the CAG expansion.
- Modeling suggested that targeting just two SNPs from different blocks could cover most European patients with allele-specific treatment.
- Of 17 SNP-directed ASOs tested, several preferentially lowered the mutant transcript over wild-type, which retains protective deubiquitinase function.
- In two iPSC-derived cortical neuron lines, a single ASO dose strongly reduced mutant ATXN3.
💡 Points
Delivery will decide this more than sequence design: single-dose selectivity in two iPSC cortical lines says little about getting ASO to the cerebellum, brainstem and spinal cord at concentrations that still spare wild-type ATXN3, since allele discrimination usually erodes as dose rises. Coverage is also a European-haplotype claim; other ancestries remain untested, and no in vivo safety data are shown.